Vassilios J. Bezzerides

Publications

1. CHD4 Interacts With TBX5 to Maintain the Gene Regulatory Network of Postnatal Atrial Cardiomyocytes. bioRxiv. 2024 Dec 05. View Abstract
2. Cardiac Applications of CRISPR/AAV-Mediated Precise Genome Editing. bioRxiv. 2024 Dec 04. View Abstract
3. Antisense Oligonucleotide Therapy for Calmodulinopathy. Circulation. 2024 Oct 08; 150(15):1199-1210. View Abstract
4. Management of ultrarare inherited arrhythmia syndromes. Heart Rhythm. 2024 Aug 16. View Abstract
5. CITED4 gene therapy protects against maladaptive cardiac remodeling after ischemia/reperfusion injury in mice. Mol Ther. 2024 Oct 02; 32(10):3683-3694. View Abstract
6. Dysregulation of N-terminal acetylation causes cardiac arrhythmia and cardiomyopathy. Res Sq. 2024 Jul 19. View Abstract
7. Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems. Nat Commun. 2024 Jul 15; 15(1):5929. View Abstract
8. Premature ventricular contractions in children and young adults: natural history and clinical implications. Europace. 2024 Mar 01; 26(3). View Abstract
9. Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor. bioRxiv. 2024 Feb 28. View Abstract
10. Author Correction: Tbx5 maintains atrial identity in postnatal cardiomyocytes by regulating an atrial-specific enhancer network. Nat Cardiovasc Res. 2023 Nov; 2(11):1095. View Abstract
11. Hypertrophic Cardiomyopathy and Ventricular Preexcitation in the Young: Cause and Accessory Pathway Characteristics. Circ Arrhythm Electrophysiol. 2023 11; 16(11):e012191. View Abstract
12. Medical cardioversion of atrial fibrillation and flutter with class IC antiarrhythmic drugs in young patients with and without congenital heart disease. J Cardiovasc Electrophysiol. 2023 12; 34(12):2545-2551. View Abstract
13. Tbx5 maintains atrial identity in post-natal cardiomyocytes by regulating an atrial-specific enhancer network. Nat Cardiovasc Res. 2023 Oct; 2(10):881-898. View Abstract
14. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci Transl Med. 2023 06 21; 15(701):eabq7839. View Abstract
15. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2023 Jul; 32(7):790-797. View Abstract
16. Radiofrequency Catheter Ablation for Pediatric Atrioventricular Nodal Reentrant Tachycardia: Impact of Age on Procedural Methods and Durable Success. J Am Heart Assoc. 2022 06 21; 11(12):e022799. View Abstract
17. Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis. Circ Genom Precis Med. 2022 06; 15(3):e003507. View Abstract
18. Pacemaker use for the treatment of reflex-mediated syncope: 40-year experience at a single paediatric institution. Cardiol Young. 2021 Oct 28; 1-6. View Abstract
19. Increased Reactive Oxygen Species-Mediated Ca2+/Calmodulin-Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities and Impaired Contraction in Barth Syndrome. Circulation. 2021 05 11; 143(19):1894-1911. View Abstract
20. Two sides of the same coin: new insights into mechanisms of ventricular fibrillation. Cardiovasc Res. 2021 03 21; 117(4):983-984. View Abstract
21. Risk Factors for Early Recurrence Following Ablation for Accessory Pathways: The Role of Consolidation Lesions. Circ Arrhythm Electrophysiol. 2020 11; 13(11):e008848. View Abstract
22. Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping. Stem Cells Transl Med. 2021 01; 10(1):68-82. View Abstract
23. Paediatric/congenital cardiology physician scientists-An endangered species. Eur J Clin Invest. 2020 Oct; 50(10):e13367. View Abstract
24. MICAL1 constrains cardiac stress responses and protects against disease by oxidizing CaMKII. J Clin Invest. 2020 09 01; 130(9):4663-4678. View Abstract
25. Value of provocative electrophysiology testing in the management of pediatric patients after congenital heart surgery. Pacing Clin Electrophysiol. 2020 09; 43(9):901-907. View Abstract
26. Gene therapy for inherited arrhythmias. Cardiovasc Res. 2020 07 15; 116(9):1635-1650. View Abstract
27. CITED4 Protects Against Adverse Remodeling in Response to Physiological and Pathological Stress. Circ Res. 2020 08 14; 127(5):631-646. View Abstract
28. Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease. J Am Heart Assoc. 2020 05 18; 9(10):e016322. View Abstract
29. AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. Circ Res. 2020 04 10; 126(8):1024-1039. View Abstract
30. Low mortality in fetal supraventricular tachycardia: Outcomes in a 30-year single-institution experience. J Cardiovasc Electrophysiol. 2020 05; 31(5):1105-1113. View Abstract
31. Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. Heart Rhythm. 2020 06; 17(6):984-990. View Abstract
32. Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence. Circulation. 2020 01 28; 141(4):285-300. View Abstract
33. Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. J Am Coll Cardiol. 2019 07 23; 74(3):346-358. View Abstract
34. Insights Into the Pathogenesis of Catecholaminergic Polymorphic Ventricular Tachycardia From Engineered Human Heart Tissue. Circulation. 2019 07 30; 140(5):390-404. View Abstract
35. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia by Inhibition of Ca2+/Calmodulin-Dependent Kinase II. Circulation. 2019 07 30; 140(5):405-419. View Abstract
36. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 03 06; 11(482). View Abstract
37. Phenotypic Characterization of Individuals With Variants in Cardiovascular Genes in the Absence of a Primary Cardiovascular Indication for Testing. Circ Genom Precis Med. 2019 03; 12(3):e002463. View Abstract
38. Differentiation of fasciculoventricular fibers from anteroseptal accessory pathways using the surface electrocardiogram. Heart Rhythm. 2019 07; 16(7):1072-1079. View Abstract
39. The Real-World Utility of the LINQ Implantable Loop Recorder in Pediatric and Adult Congenital Heart Patients. JACC Clin Electrophysiol. 2019 02; 5(2):245-251. View Abstract
40. Dual-Site Ventricular Pacing in Patients With Fontan Physiology and Heart Block: Does it Mitigate the Detrimental Effects of Single-Site Ventricular Pacing? JACC Clin Electrophysiol. 2018 10; 4(10):1289-1297. View Abstract
41. Channelopathy as a SUDEP Biomarker in Dravet Syndrome Patient-Derived Cardiac Myocytes. Stem Cell Reports. 2018 09 11; 11(3):626-634. View Abstract
42. Utility of incomplete right bundle branch block as an isolated ECG finding in children undergoing initial cardiac evaluation. Congenit Heart Dis. 2018 May; 13(3):419-427. View Abstract
43. Low molecular weight heparin as an anticoagulation strategy for left-sided ablation procedures. Congenit Heart Dis. 2018 Mar; 13(2):222-225. View Abstract
44. Genotype-phenotype-guided medical and surgical intervention in long QT syndrome. HeartRhythm Case Rep. 2018 Jan; 4(1):14-17. View Abstract
45. Mitochondrial Cardiomyopathy Caused by Elevated Reactive Oxygen Species and Impaired Cardiomyocyte Proliferation. Circ Res. 2018 01 05; 122(1):74-87. View Abstract
46. Cardiac Events During Competitive, Recreational, and Daily Activities in Children and Adolescents With Long QT Syndrome. J Am Heart Assoc. 2017 Sep 21; 6(9). View Abstract
47. Inhibition of serum and glucocorticoid regulated kinase-1 as novel therapy for cardiac arrhythmia disorders. Sci Rep. 2017 03 23; 7(1):346. View Abstract
48. Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Circ J. 2016 Dec 22; 81(1):12-21. View Abstract
49. Pausing With the Gauze: Inhibition of Temporary Pacemakers by Radiofrequency Scan During Cardiac Surgery. Anesth Analg. 2016 11; 123(5):1143-1148. View Abstract
50. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Dev Cell. 2016 11 21; 39(4):466-479. View Abstract
51. S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling. Arterioscler Thromb Vasc Biol. 2016 09; 36(9):1854-67. View Abstract
52. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. JCI Insight. 2016 Jun 16; 1(9). View Abstract
53. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 2015 Apr 07; 21(4):584-95. View Abstract
54. Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J Mol Cell Cardiol. 2014 Jul; 72:74-84. View Abstract
55. Saying yes to exercise and NO to cardiac injury. Circ Res. 2011 Jun 10; 108(12):1414-6. View Abstract
56. Rapid vesicular translocation and insertion of TRP channels. Nat Cell Biol. 2004 Aug; 6(8):709-20. View Abstract
57. SPIE- The International Society for Optical Engineering. Near-membrane protein dynamics revealed by evanescent field microscopy. 2004; (5467):326-337. View Abstract
58. Mechanism of persistent protein kinase D1 translocation and activation. Dev Cell. 2003 Apr; 4(4):561-74. View Abstract
59. The effects of buoyancy on sonoluminescing bubbles. Acoustics research letters online : ARLO. 2000; (1):12-18. View Abstract
60. The search for electrical discharges from single- and multi-bubble sonoluminescence. The Journal of the Acoustical Society of America. 1999; 1020(105). View Abstract
Show All Publications Show Fewer Publications